News Releases

Date Title
09/30/2016 Summary ToggleEnanta Pharmaceuticals Announces AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
09/29/2016 Summary ToggleEnanta Pharmaceuticals Presents Data on a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV) at the 10th Annual Respiratory Syncytial Virus Conference
09/28/2016 Summary ToggleEnanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)
09/23/2016 Summary ToggleEnanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
08/29/2016 Summary ToggleEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
08/08/2016 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2016
07/25/2016 Summary ToggleEnanta Announces the U.S. Food and Drug Administration has approved AbbVie’s New, Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C Virus
07/18/2016 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 P.M. ET to Discuss Financial Results for Its Fiscal Third Quarter Ended June 30, 2016
06/20/2016 Summary ToggleEnanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus
06/01/2016 Summary ToggleEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences